Evaluation of spin labeled TEPA and CCNU analogs against osteosarcoma and MNU-induced mammary carcinoma of the SD-rat.
The effectiveness to reduce tumor growth by 1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)- 1-nitrosourea (SLCNU) and N,N,N,'N'- bis(1,2-ethanediyl)-N"-(1-oxyl-2,2,6,6-tetramethyl- 2-piperidinylaminocarbonyl)-phosphoric triamide (SLDU) was studied in osteosarcoma and MNU-induced mammary carcinoma in the SD-rat. Both compounds elicited neither an inhibitory effect on these tumors nor an increase in the mean/median life span as compared to the control group.
Klenner
T
T
German Cancer Research Center, Heidelberg, FRG.
Berger
M R
MR
Sosnovsky
G
G
Rao
N U
NU
Wingen
F
F
Schmähl
D
D
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D003497:Cyclic N-Oxides; D004305:Dose-Response Relationship, Drug; D005038:Ethylnitrosourea / Q000031:analogs & derivatives*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D008770:Methylnitrosourea; D009368:Neoplasm Transplantation; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D013721:Triethylenephosphoramide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001389:Azirines; D003497:Cyclic N-Oxides; D009607:Nitrosourea Compounds; D008770:Methylnitrosourea; C045032:1-(2-chloroethyl)-3-(1-oxyl-2,2,6,6-tetramethylpiperidinyl)-1-nitrosourea; C045031:N,N,N',N'-bis(1,2-ethanediyl)-N''-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinylaminocarbonyl)phosphoric triamide; D013721:Triethylenephosphoramide; D005038:Ethylnitrosourea